Cardiac Arrhythmia Suppression Trial (CAST) - randomized controlled trial designed to test the hypothesis that suppression of premature ventricular complexes (PVC) with class I antiarrhythmic agents after a myocardial infarction (MI) would reduce mortality.[2][3]
Atrial fibrillation
Coronary artery disease
Epidemiology
Busselton Health Study - a prospective cohort study of residents of the Western Australian city of Busselton regarding cardiovascular disease, pulmonary function, diabetes, and cancer.[4]
Caerphilly Heart Disease Study - prospective cohort study of the residents from Caerphilly, South Wales, to examine relationships between a wide range of social, lifestyle, dietary, and other factors with incident vascular disease.[5]
Framingham Heart Study - long-term, ongoing cardiovascular cohort study of residents of the city of Framingham, Massachusetts.[6]
Nurses' Health Study - series of prospective studies that examine epidemiology and the long-term effects of nutrition, hormones, environment, and nurses' work-life on health and disease development.[7]
Seven Countries Study - a prospective cohort study that examined the relationships between lifestyle, diet, coronary heart disease, and stroke in different populations.[8]
Strong Heart Study - cohort study of cardiovascular disease (CVD) and its risk factors among American Indian men and women.[9]
Heart failure
Multicenter Automatic Defibrillator Implantation Trial (MADIT) - a series of randomized controlled trials designed to test the hypothesis that implantable cardioverter defibrillator (ICD) therapy in moderately high-risk coronary patients would significantly reduce death.[10]
RALES (trial) - randomized controlled trial comparing spironolactone to placebo when added to standard care in patients with advanced heart failure.[11]
AIM-HIGH (trial) - a randomized controlled trial of niacin for increasing HDL levels.[14]
HDL-Atherosclerosis Treatment Study (HATS) - a randomized controlled trial that studied people with coronary heart disease and compared a combination of simvastatin and niacin with antioxidant vitamin therapy.[15]
Heart Protection Study - a randomized controlled trial that studied the cholesterol-lowering drug simvastatin and vitamin supplementation in people at risk of cardiovascular disease.[16]
JUPITER trial - a randomized controlled trial to evaluate whether statins reduce heart attacks and strokes in people with normal cholesterol levels.[17]
PROVE-IT TIMI 22 - a randomized controlled trial that compared intensive vs. moderate-dose statin therapy immediately after a heart attack.[18]
Scandinavian Simvastatin Survival Study (4S) - a randomized controlled trial that studied the use of the cholesterol-lowering drug simvastatin in people with moderately raised cholesterol and coronary heart disease.[19]
West of Scotland Coronary Prevention Study (WOSCOPS) - a randomized controlled trial that compared the cholesterol-lowering drug pravastatin in patients with no previous history of a heart attack.[20]
Valvular diseases
References
^Hennekens, Charles H. (February 1998). "Trials of Thrombolytic Therapy : The International Studies of Infarct Survival Experience". Journal of Interventional Cardiology. 11 (1): 1–7. doi:10.1111/j.1540-8183.1998.tb00089.x.
^Cardiac Arrhythmia Suppression Trial (CAST) Investigators (10 August 1989). "Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction". New England Journal of Medicine. 321 (6): 406–412. doi:10.1056/NEJM198908103210629. PMID2473403.
^Echt, Debra S.; Liebson, Philip R.; Mitchell, L. Brent; et al. (21 March 1991). "Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial". New England Journal of Medicine. 324 (12): 781–788. doi:10.1056/NEJM199103213241201. PMID1900101.
^Cullen, K. J. (September 1972). "Mass Health Examinations in the Busselton Population, 1966 to 1970". Medical Journal of Australia. 2 (13): 714–718. doi:10.5694/j.1326-5377.1972.tb103506.x. PMID5084969.
^Belanger, CF; Hennekens, CH; Rosner, B; et al. (June 1978). "The nurses' health study". The American Journal of Nursing. 78 (6): 1039–40. PMID248266.
^Keys, Ancel; Taylor, Henry Longstreet; Blackburn, Henry; et al. (September 1963). "Coronary Heart Disease among Minnesota Business and Professional Men Followed Fifteen Years". Circulation. 28 (3): 381–395. doi:10.1161/01.CIR.28.3.381. PMID14059458.
^Howard, Barbara V.; Lee, Elisa T.; Cowan, Linda D.; et al. (11 May 1999). "Rising Tide of Cardiovascular Disease in American Indians: The Strong Heart Study". Circulation. 99 (18): 2389–2395. doi:10.1161/01.cir.99.18.2389. PMID10318659.
^Moss, Arthur J.; Hall, W. Jackson; Cannom, David S.; et al. (26 December 1996). "Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia". New England Journal of Medicine. 335 (26): 1933–1940. doi:10.1056/NEJM199612263352601. PMID8960472.
^Pitt, Bertram; Zannad, Faiez; Remme, Willem J.; et al. (2 September 1999). "The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure". New England Journal of Medicine. 341 (10): 709–717. doi:10.1056/NEJM199909023411001. PMID10471456.
^The Allhat Officers And Coordinators For The Allhat Collaborative Research Group (18 December 2002). "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)". JAMA: The Journal of the American Medical Association. 288 (23): 2981–2997. doi:10.1001/jama.288.23.2981. PMID12479763.
^SPRINT Research Group; Wright Jr, J. T.; Williamson, J. D.; Whelton, P. K.; Snyder, J. K.; Sink, K. M.; Rocco, M. V.; Reboussin, D. M.; Rahman, M.; Oparil, S.; Lewis, C. E.; Kimmel, P. L.; Johnson, K. C.; Goff Jr, D. C.; Fine, L. J.; Cutler, J. A.; Cushman, W. C.; Cheung, A. K.; Ambrosius, W. T. (26 November 2015). "A Randomized Trial of Intensive versus Standard Blood-Pressure Control". New England Journal of Medicine. 373 (22): 2103–2116. doi:10.1056/NEJMoa1511939. PMC4689591. PMID26551272.
^Boden, William E; Probstfield, Jeffrey L; Anderson, Todd; et al. (15 December 2011). "Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy". New England Journal of Medicine. 365 (24): 2255–2267. doi:10.1056/nejmoa1107579. PMID22085343.
^Kastelein, John J.P.; Akdim, Fatima; Stroes, Erik S.G.; et al. (3 April 2008). "Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia". New England Journal of Medicine. 358 (14): 1431–1443. doi:10.1056/NEJMoa0800742. PMID18376000.
^Heart Protection Study Collaborative Group (July 2002). "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial". The Lancet. 360 (9326): 7–22. doi:10.1016/S0140-6736(02)09327-3. PMID12114036.
^Ridker, Paul M; Danielson, Eleanor; Fonseca, Francisco A.H.; et al. (20 November 2008). "Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein". New England Journal of Medicine. 359 (21): 2195–2207. doi:10.1056/NEJMoa0807646. PMID18997196.
^Cannon, Christopher P.; Braunwald, Eugene; McCabe, Carolyn H.; et al. (8 April 2004). "Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes". New England Journal of Medicine. 350 (15): 1495–1504. doi:10.1056/NEJMoa040583. PMID15007110.
^"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)". Lancet. 344 (8934): 1383–9. 19 November 1994. PMID7968073.
^Shepherd, James; Cobbe, Stuart M.; Ford, Ian; et al. (16 November 1995). "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia". New England Journal of Medicine. 333 (20): 1301–1308. doi:10.1056/NEJM199511163332001. PMID7566020.